This immune diagnostics firm reported a notable insider sale as it expands its clinical portfolio and strategic partnerships.

This Seattle-based biotech, known for its immune medicine platform, reported a notable insider sale amid ongoing industry ...

Detailed price information for Adaptive Biotechnologies Corp (ADPT-Q) from The Globe and Mail including charting and trades.

Transaction value based on SEC Form 4 weighted average purchase price ($13.21). Adaptive Biotechnologies operates at scale in the biotechnology sector, focusing on immune medicine platforms for ...

The commercial-stage Adaptive booked $58.9 million in revenue for the period, a robust 36% improvement over the same quarter of 2024. Much of this growth was due to the company's efforts fighting ...

SEATTLE, Jan. 22, 2026 (GLOBE NEWSWIRE) -- Adaptive Biotechnologies Corporation (ADPT), a commercial stage biotechnology company that aims to translate the genetics of the adaptive immune system into ...

SEATTLE, Dec. 15, 2025 (GLOBE NEWSWIRE) -- Adaptive Biotechnologies Corporation (ADPT), a commercial stage biotechnology company that aims to translate the genetics of the adaptive immune system into ...

SEATTLE, Dec. 06, 2025 (GLOBE NEWSWIRE) -- Adaptive Biotechnologies Corporation (Nasdaq: ADPT), a commercial stage biotechnology company that aims to translate the genetics of the adaptive immune ...

Adaptive Biotechnologies Corporation (Nasdaq: ADPT), a commercial stage biotechnology company that aims to translate the genetics of the adaptive immune system into clinical products to diagnose and ...

Shares of Adaptive Biotechnologies (ADPT) have been strong performers lately, with the stock up 14.5% over the past month. The stock hit a new 52-week high of $12.93 in the previous session. Adaptive ...

Adaptive Biotechnologies Corporation (NASDAQ:ADPT) Q4 2025 Earnings Call Transcript February 5, 2026 Adaptive Biotechnologies Corporation beats earnings expectations. Reported EPS is $-0.08868, ...

Adaptive Biotechnologies this week announced the development of a new technology that could help improve T-cell immunotherapy. The company will hire 50 people to help ...